Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosdenopterin Switch Study in Pediatric MoCD Type A
NCT02047461Phase 2Completed
- Sponsor
- Origin Biosciences
- Start
- Apr 2014
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs
- Countries
- 5
01
Overview
A Phase 2 trial of fosdenopterin in molybdenum cofactor deficiency type A (MoCD-A), sponsored by Origin Biosciences. Started Apr 2014; status: completed.
02
Drugs
fosdenopterin
03
Conditions
molybdenum cofactor deficiency type A (MoCD-A)
Beyond the preview
Go deeper on NCT02047461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047461.